SPRB vs. ACST, APM, LPCN, APRE, ACXP, LEXX, EYEN, ALRN, DRRX, and TCRT
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Acasti Pharma (ACST), Aptorum Group (APM), Lipocine (LPCN), Aprea Therapeutics (APRE), Acurx Pharmaceuticals (ACXP), Lexaria Bioscience (LEXX), Eyenovia (EYEN), Aileron Therapeutics (ALRN), DURECT (DRRX), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical preparations" industry.
Acasti Pharma (NASDAQ:ACST) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.
In the previous week, Acasti Pharma had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 1 mentions for Acasti Pharma and 0 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.49 beat Acasti Pharma's score of 0.00 indicating that Acasti Pharma is being referred to more favorably in the media.
Acasti Pharma has a net margin of 0.00% compared to Acasti Pharma's net margin of -474.96%. Spruce Biosciences' return on equity of -13.18% beat Acasti Pharma's return on equity.
6.1% of Acasti Pharma shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 13.5% of Acasti Pharma shares are owned by insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Acasti Pharma currently has a consensus target price of $6.00, indicating a potential upside of 95.44%. Spruce Biosciences has a consensus target price of $5.67, indicating a potential upside of 697.78%. Given Acasti Pharma's higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Acasti Pharma.
Acasti Pharma has higher earnings, but lower revenue than Spruce Biosciences. Acasti Pharma is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Acasti Pharma received 273 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 70.52% of users gave Acasti Pharma an outperform vote while only 64.41% of users gave Spruce Biosciences an outperform vote.
Acasti Pharma has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.
Summary
Acasti Pharma beats Spruce Biosciences on 10 of the 17 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
